Literature DB >> 2160478

Histogenesis of ovarian malignant mixed mesodermal tumours.

T J Clarke1.   

Abstract

The histogenesis of ovarian malignant mixed mesodermal tumours, which includes the concept of metaplastic carcinoma, is controversial. Four such tumours were examined for evidence of metaplastic transition from carcinoma to sarcoma using morphology and reticulin stains. Consecutive sections were stained immunohistochemically using cytokeratin and vimentin to determine whether cells at the interface between carcinoma and sarcoma expressed both cytokeratin and vimentin. There was no evidence of morphological, architectural, or immunohistochemical transitions from carcinoma to sarcoma in the four tumours studied. This suggests that ovarian malignant mixed mesodermal tumours are not metaplastic carcinomas but are composed of histogenetically different elements.

Entities:  

Mesh:

Year:  1990        PMID: 2160478      PMCID: PMC502355          DOI: 10.1136/jcp.43.4.287

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  28 in total

1.  Mixed mesodermal tumor and clear cell carcinoma arising in ovarian endometriosis.

Authors:  P Cooper
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

Review 2.  Primary ovarian sarcomas. Report of 43 cases from the Emil Novak Ovarian Tumor Registry.

Authors:  R S Azoury; J D Woodruff
Journal:  Obstet Gynecol       Date:  1971-06       Impact factor: 7.661

3.  Carcinosarcomas and mixed mesodermal tumors of the ovary.

Authors:  L P Dehner; H J Norris; H B Taylor
Journal:  Cancer       Date:  1971-01       Impact factor: 6.860

4.  Carcinosarcoma and mixed mesodermal tumor of the ovary. A clinicopathologic analysis of 9 cases.

Authors:  B Czernobilsky; G C LaBarre
Journal:  Obstet Gynecol       Date:  1968-01       Impact factor: 7.661

5.  Carcinosarcoma of the ovary.

Authors:  M E Fenn; M R Abell
Journal:  Am J Obstet Gynecol       Date:  1971-08-15       Impact factor: 8.661

6.  Co-expression of vimentin and cytokeratins in parietal endoderm cells of early mouse embryo.

Authors:  E B Lane; B L Hogan; M Kurkinen; J I Garrels
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

7.  Malignant mixed mesodermal tumors of the ovary: a clinicopathologic assessment of 12 cases.

Authors:  K W Barwick; V A LiVolsi
Journal:  Am J Surg Pathol       Date:  1980-02       Impact factor: 6.394

8.  Ovarian malignant mixed mesodermal tumor: the occurrence of hyaline droplets containing alpha 1-antitrypsin.

Authors:  M Dictor
Journal:  Hum Pathol       Date:  1982-10       Impact factor: 3.466

9.  Alpha-1-antitrypsin in a malignant mixed mesodermal tumor of the ovary.

Authors:  M Dictor
Journal:  Am J Surg Pathol       Date:  1981-09       Impact factor: 6.394

10.  Bilateral ovarian endometriosis associated with carcinosarcoma of the right ovary and endometrioid carcinoma of the left ovary.

Authors:  A M Marchevsky; M Kaneko
Journal:  Am J Clin Pathol       Date:  1978-10       Impact factor: 2.493

View more
  1 in total

1.  Prognostic impact of chromosome aberrations in ovarian cancer.

Authors:  T Pejovic; A Himmelmann; S Heim; N Mandahl; U M Flodérus; S Furgyik; B Elmfors; G Helm; H Willén; F Mitelman
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.